Q1-FY26 · Rashesh Gogri
Even though the revenue has been slightly dip in this quarter year on year, the EBITDA and the PAT have grown reasonably well.
AARTIPHARM / language trends
Read confidence between the lines.
Aarti Pharmalabs · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q1-FY26 · Rashesh Gogri
We are the only backward integrated independent of China source from India who can offer them Zanthin products at a reasonable price.
Q1-FY26 · Rashesh Gogri
In three four years, we want all segments to grow up to 100 million or thousand crore, whichever reaches faster.
Q3-FY26 · Rash Gori
We are confident of meeting our CDMO revenue guidance for FI26. However, exceeding that target which was earlier possibility now looks difficult due to certain project deliveries getting pushed by a few months.
Q3-FY26 · Rash Gori
API business continues to see some margin pressure while early indication of recovery are emerging.
Q3-FY26 · Management
We are not commenting on specific molecule because of the CDA that we have with various customers.
Q4-FY26 · Rashesh Gogri
We are targeting 15 to 18% growth in both revenue and EBITDA for next three four years.
Q4-FY26 · Rashesh Gogri
For immediate FY27, we expect the CDMO CMO business to lead the growth with a projected sales growth of 40 to 50%.
Q4-FY26 · Rashesh Gogri
We have projected line of sight of close to $100 million in CDMO segment going forward.